DK2209778T3 - Pyridin-2-yl-amino-1, 2, 4-thiadiazolderivater som glucokinase-aktivatorer til behandling af diabetes mellitus - Google Patents

Pyridin-2-yl-amino-1, 2, 4-thiadiazolderivater som glucokinase-aktivatorer til behandling af diabetes mellitus

Info

Publication number: DK2209778T3
Authority: DK; Denmark
Prior art keywords: pyridin; amino; treatment; diabetes mellitus; glucokinase activators
Prior art date: 2007-09-21

Application number

DK08834504.6T

Other languages

English (en)

Inventor

John P Fischer

Thomas Daniel Aicher

Mark Joseph Chicarelli

Kevin Ronald Condroski

Jay Bradford Fell

Steven Armen Boyd

Indrani W Gunawardana

Ronald Jay Hinklin

Ajay Singh

Timothy M Turner

Eli M Wallace

Original Assignee

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-21

Filing date

2008-09-15

Publication date

2012-09-17

2008-09-15 Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc

2012-09-17 Application granted granted Critical

2012-09-17 Publication of DK2209778T3 publication Critical patent/DK2209778T3/da

Links

BOQQUDFKYXJRGO-UHFFFAOYSA-N 5-pyridin-2-yl-1,2,4-thiadiazol-3-amine Chemical class NC1=NSC(C=2N=CC=CC=2)=N1 BOQQUDFKYXJRGO-UHFFFAOYSA-N 0.000 title 1
102000030595 Glucokinase Human genes 0.000 title 1
108010021582 Glucokinase Proteins 0.000 title 1
239000012190 activator Substances 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)

DK08834504.6T 2007-09-21 2008-09-15 Pyridin-2-yl-amino-1, 2, 4-thiadiazolderivater som glucokinase-aktivatorer til behandling af diabetes mellitus DK2209778T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97422507P	2007-09-21	2007-09-21
PCT/US2008/076401 WO2009042435A1 (en)	2007-09-21	2008-09-15	Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus

Publications (1)

Publication Number	Publication Date
DK2209778T3 true DK2209778T3 (da)	2012-09-17

Family

ID=40250949

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08834504.6T DK2209778T3 (da)	2007-09-21	2008-09-15	Pyridin-2-yl-amino-1, 2, 4-thiadiazolderivater som glucokinase-aktivatorer til behandling af diabetes mellitus

Country Status (28)

Country	Link
US (3)	US8212045B2 (da)
EP (4)	EP3078662A1 (da)
JP (1)	JP5722037B2 (da)
KR (1)	KR101566042B1 (da)
CN (1)	CN101868459B (da)
AR (1)	AR068628A1 (da)
AU (1)	AU2008305294B2 (da)
BR (1)	BRPI0816881A2 (da)
CA (1)	CA2699718C (da)
CO (1)	CO6270223A2 (da)
CR (2)	CR11383A (da)
DK (1)	DK2209778T3 (da)
EA (1)	EA019104B1 (da)
ES (2)	ES2569734T3 (da)
HR (1)	HRP20120814T1 (da)
IL (1)	IL204264A (da)
MA (1)	MA31779B1 (da)
MX (1)	MX2010002772A (da)
MY (1)	MY180558A (da)
NZ (1)	NZ583538A (da)
PL (1)	PL2209778T3 (da)
PT (1)	PT2209778E (da)
SI (1)	SI2209778T1 (da)
TN (1)	TN2010000100A1 (da)
TW (1)	TWI423799B (da)
UA (1)	UA101166C2 (da)
WO (1)	WO2009042435A1 (da)
ZA (2)	ZA201002206B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2131656A4 (en) *	2006-11-15	2011-12-07	Forest Lab Holdings Ltd	phthalazine
EA019104B1 (ru)	2007-09-21	2014-01-30	Эррей Биофарма Инк.	Активаторы глюкокиназы
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2800498C (en)	2010-03-31	2021-11-16	The Scripps Research Institute	Reprogramming cells
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
MX2013002208A (es)	2010-08-23	2013-05-30	Amgen Inc	Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
KR20140051834A (ko)	2011-03-09	2014-05-02	다이이찌 산쿄 가부시키가이샤	디피리딜아민 유도체
WO2012138776A1 (en)	2011-04-05	2012-10-11	Amgen Inc.	Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104230892B (zh) *	2011-11-09	2016-12-07	福建海西新药创制有限公司	一组提高激酶活性的化合物及其应用
WO2013123444A1 (en)	2012-02-17	2013-08-22	Amgen Inc.	Sulfonyl compounds that interact with glucokinase regulatory protein
WO2013173382A1 (en)	2012-05-15	2013-11-21	Amgen Inc.	Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
EP2850057A4 (en) *	2012-05-18	2016-01-27	Amgen Inc	PROCESS FOR THE PREPARATION OF THIADIAZOLENE
US20150299182A1 (en) *	2012-11-09	2015-10-22	Amgen Inc.	Crystalline forms of (1s)-1-[5-(amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol
WO2016059647A2 (en) *	2014-10-13	2016-04-21	SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India)	Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
GB201714777D0 (en)	2017-09-14	2017-11-01	Univ London Queen Mary	Agent
BR112020008727A2 (pt)	2017-10-30	2020-10-20	Neuropore Therapies, Inc.	fenil sulfonil fenil triazol tionas substituídas e usos destas
BR112020024269A2 (pt) *	2018-05-31	2021-02-23	Hua Medicine (Shanghai) Ltd.	combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3983246A (en)	1974-04-04	1976-09-28	Fmc Corporation	N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents
DE2949913A1 (de) *	1979-12-12	1981-06-25	Basf Ag, 6700 Ludwigshafen	Azofarbstoffe
EP0300688A1 (en)	1987-07-21	1989-01-25	FISONS plc	Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0228168A (ja) *	1988-04-14	1990-01-30	Sankyo Co Ltd	チアゾール誘導体
WO1993017681A1 (en)	1992-03-02	1993-09-16	Abbott Laboratories	Angiotensin ii receptor antagonists
WO1993024442A1 (fr)	1992-05-29	1993-12-09	Yamanouchi Pharmaceutical Co., Ltd.	Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique
JP3056788B2 (ja)	1994-06-24	2000-06-26	ユーロ−セルティーク，エス．エイ．	ホスホジエステラーゼｉｖの阻害化合物および阻害方法
GB9908410D0 (en) *	1999-04-13	1999-06-09	Pfizer Ltd	Pyridines
CA2366932C (en)	1999-04-15	2009-08-25	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
HRP20010795A2 (en)	1999-04-28	2003-02-28	Aventis Pharma Gmbh	Di-aryl acid derivatives as ppar receptor ligands
US6465467B1 (en)	1999-05-21	2002-10-15	Biovitrum Ab	Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
CA2374898C (en)	1999-05-21	2009-12-08	Biovitrum Ab	Pyrazinyl-piperazine compounds, their use and preparation
JP4144978B2 (ja)	1999-09-09	2008-09-03	富士フイルム株式会社	１，２，４−チアジアゾール誘導体の合成法
MXPA02002559A (es)	1999-09-10	2002-07-30	Merck & Co Inc	Inhibidores de tirosina cinasa.
CA2396693A1 (en)	1999-12-28	2001-07-05	Stephen T. Wrobleski	Cytokine, especially tnf-alpha, inhibitors
US6906067B2 (en)	1999-12-28	2005-06-14	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
US7345051B2 (en)	2000-01-31	2008-03-18	Genaera Corporation	Mucin synthesis inhibitors
DZ3398A1 (fr)	2000-08-31	2002-03-07	Pfizer Prod Inc	Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
US20050209297A1 (en)	2000-08-31	2005-09-22	Pfizer Inc	Pyrazole derivatives
AU2002213467A1 (en)	2000-10-11	2002-04-22	Chemocentryx, Inc.	Modulation of ccr4 function
WO2002030357A2 (en)	2000-10-11	2002-04-18	Chemocentryx, Inc.	Compounds and methods for modulating ccr4 function
AU3950802A (en)	2000-12-07	2002-06-18	Cv Therapeutics Inc	Abca-1 elevating compounds
BR0116493A (pt)	2000-12-21	2003-09-30	Vertex Pharma	Compostos de pirazol úteis como inibidores de proteìna cinase
AU2002258400A1 (en)	2001-02-16	2002-08-28	Tularik Inc.	Methods of using pyrimidine-based antiviral agents
WO2002094264A1 (en)	2001-05-23	2002-11-28	Tularik Inc.	Ccr4 antagonists
CA2450934A1 (en)	2001-06-19	2002-12-27	Marco Dodier	Pyrimidine inhibitors of phosphodiesterase (pde) 7
PE20030008A1 (es)	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
ATE316088T1 (de) *	2001-06-22	2006-02-15	Merck & Co Inc	Tyrosin-kinase inhibitoren
EP1465900B1 (en)	2002-01-10	2008-05-14	Bayer HealthCare AG	Rho-kinase inhibitors
ATE511858T1 (de)	2002-02-05	2011-06-15	Astellas Pharma Inc	2,4,6-triamino-1,3,5-triazin-derivat
US6846928B2 (en)	2002-03-15	2005-01-25	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
AU2003225800A1 (en)	2002-03-15	2003-09-29	Hayley Binch	Azolylaminoazine as inhibitors of protein kinases
US20040009981A1 (en)	2002-03-15	2004-01-15	David Bebbington	Compositions useful as inhibitors of protein kinases
WO2003077921A1 (en)	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azinylaminoazoles as inhibitors of protein kinases
MXPA04009541A (es)	2002-03-29	2005-01-25	Chiron Corp	Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
US8299108B2 (en)	2002-03-29	2012-10-30	Novartis Ag	Substituted benzazoles and methods of their use as inhibitors of raf kinase
AU2003227360A1 (en) *	2002-04-25	2003-11-10	Yamanouchi Pharmaceutical Co., Ltd.	Novel amide derivatives or salts thereof
AU2003249369A1 (en)	2002-06-21	2004-01-06	Cellular Genomics, Inc.	Certain amino-substituted monocycles as kinase modulators
CN1691944A (zh)	2002-08-09	2005-11-02	阿斯利康(瑞典)有限公司	作为代谢型谷氨酸受体－5调节剂的噁二唑
WO2004024159A1 (en)	2002-09-10	2004-03-25	Scios Inc.	INHIBITORS OF TFGβ
PL375021A1 (en)	2002-10-03	2005-11-14	Novartis Ag	Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
EP1558609A4 (en)	2002-10-30	2008-05-28	Merck & Co Inc	KINASE INHIBITORS
CA2755297A1 (en)	2003-02-10	2004-08-26	Vertex Pharmaceuticals Incorporated	Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
US20040248850A1 (en)	2003-02-11	2004-12-09	Kemia, Inc.	Compounds for the treatment of HIV infection
BRPI0407283A (pt)	2003-02-13	2006-01-31	Banyu Pharma Co Ltd	Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
ATE396731T1 (de)	2003-03-25	2008-06-15	Vertex Pharma	Thiazole zur verwendung als inhibitoren von protein-kinasen
US7244763B2 (en)	2003-04-17	2007-07-17	Warner Lambert Company Llc	Compounds that modulate PPAR activity and methods of preparation
CN1845915A (zh)	2003-09-02	2006-10-11	默克公司	作为亲代谢谷氨酸受体－5的调节剂的联吡啶胺和醚类化合物
US7470712B2 (en)	2004-01-21	2008-12-30	Bristol-Myers Squibb Company	Amino-benzazoles as P2Y1 receptor inhibitors
WO2005077373A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
AR049418A1 (es)	2004-02-27	2006-08-02	Bayer Pharmaceuticals Corp	Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
KR20050091462A (ko)	2004-03-12	2005-09-15	한국과학기술연구원	푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
AU2005223610B2 (en)	2004-03-23	2008-05-29	Banyu Pharmaceutical Co., Ltd.	Substituted quinazoline or pyridopyrimidine derivative
US7781451B2 (en)	2004-04-02	2010-08-24	Novartis Ag	Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
US7642354B2 (en)	2004-04-13	2010-01-05	Icagen, Inc.	Polycyclic pyrazines as potassium ion channel modulators
EP1737852A2 (en)	2004-04-13	2007-01-03	Icagen, Inc.	Polycyclic pyridines as potassium ion channel modulators
TW200606129A (en) *	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1844023A1 (en)	2004-12-31	2007-10-17	Sk Chemicals Co., Ltd.	Quinazoline derivatives for the treatment and prevention of diabetes and obesity
MX2007008434A (es)	2005-01-19	2007-07-25	Squibb Bristol Myers Co	Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
DE102005025161A1 (de)	2005-06-01	2006-12-07	Phenion Gmbh & Co. Kg	Derivate des Pyrimidins und Triazins und deren Verwendung
US7737151B2 (en)	2005-08-18	2010-06-15	Vertex Pharmaceuticals Incorporated	Pyrazine kinase inhibitors
AU2006285834A1 (en) *	2005-08-31	2007-03-08	Astellas Pharma Inc.	Thiazole derivative
WO2007038387A2 (en)	2005-09-23	2007-04-05	Yale University	Compounds and methods for the treatment of viruses and cancer
EP1948652B1 (en)	2005-11-01	2011-08-24	Array Biopharma, Inc.	Glucokinase activators
JP5249770B2 (ja)	2005-11-03	2013-07-31	バーテックスファーマシューティカルズインコーポレイテッド	キナーゼインヒビターとして有用なアミノピリジン
KR20070052207A (ko)	2005-11-16	2007-05-21	주식회사 엘지생명과학	신규한 ｋｄｒ 억제제
ATE508126T1 (de)	2005-11-16	2011-05-15	Vertex Pharma	Als kinaseinhibitoren geeignete aminopyrimidine
JP5236499B2 (ja) *	2006-01-27	2013-07-17	アレイバイオファーマ、インコーポレイテッド	グルコキナーゼ活性化剤
RS53981B1 (sr) *	2006-03-24	2015-10-30	Array Biopharma Inc.	Analozi 2-aminopiridina kao aktivatori glukokinaze
WO2007131953A1 (en)	2006-05-12	2007-11-22	Ab Science	A new process for the synthesis of 2-aminoxazole compounds
WO2008024963A1 (en)	2006-08-24	2008-02-28	Serenex, Inc.	Benzene, pyridine, and pyridazine derivatives
TW200825060A (en)	2006-10-26	2008-06-16	Astrazeneca Ab	Chemical compounds
JP5208123B2 (ja)	2006-12-08	2013-06-12	アイアールエム・リミテッド・ライアビリティ・カンパニー	タンパク質キナーゼ阻害剤としての化合物および組成物
US8431713B2 (en)	2007-01-24	2013-04-30	Array Biopharma, Inc.	2-aminopyridine derivatives as glucokinase activators
JP5450108B2 (ja) *	2007-03-23	2014-03-26	アレイバイオファーマ、インコーポレイテッド	グルコキナーゼ活性化剤としての２−アミノピリジン類似体
ES2470341T3 (es)	2007-04-05	2014-06-23	Amgen, Inc	Moduladores de la aurora cinasa y método de uso
US20090012091A1 (en)	2007-07-02	2009-01-08	Kinagen, Inc.	Oximide derivatives and their therapeutical application
WO2009022171A1 (en)	2007-08-13	2009-02-19	Astrazeneca Ab	Pyridinyiioxy pyridines as alk5 inhibitors
EA019104B1 (ru)	2007-09-21	2014-01-30	Эррей Биофарма Инк.	Активаторы глюкокиназы
KR20100090250A (ko)	2007-10-09	2010-08-13	메르크 파텐트 게엠베하	글루코키나제 활성체로서 유용한 피리딘 유도체

2008
- 2008-09-15 EA EA201000515A patent/EA019104B1/ru not_active IP Right Cessation
- 2008-09-15 UA UAA201004782A patent/UA101166C2/ru unknown
- 2008-09-15 ES ES13186328.4T patent/ES2569734T3/es active Active
- 2008-09-15 HR HRP20120814AT patent/HRP20120814T1/hr unknown
- 2008-09-15 BR BRPI0816881 patent/BRPI0816881A2/pt not_active IP Right Cessation
- 2008-09-15 NZ NZ583538A patent/NZ583538A/en not_active IP Right Cessation
- 2008-09-15 CN CN2008801169950A patent/CN101868459B/zh not_active Expired - Fee Related
- 2008-09-15 PL PL08834504T patent/PL2209778T3/pl unknown
- 2008-09-15 MX MX2010002772A patent/MX2010002772A/es active IP Right Grant
- 2008-09-15 JP JP2010525902A patent/JP5722037B2/ja not_active Expired - Fee Related
- 2008-09-15 AU AU2008305294A patent/AU2008305294B2/en not_active Ceased
- 2008-09-15 EP EP16160414.5A patent/EP3078662A1/en not_active Withdrawn
- 2008-09-15 DK DK08834504.6T patent/DK2209778T3/da active
- 2008-09-15 KR KR1020107008594A patent/KR101566042B1/ko not_active Expired - Fee Related
- 2008-09-15 US US12/678,995 patent/US8212045B2/en not_active Expired - Fee Related
- 2008-09-15 SI SI200830746T patent/SI2209778T1/sl unknown
- 2008-09-15 CA CA2699718A patent/CA2699718C/en not_active Expired - Fee Related
- 2008-09-15 EP EP13186328.4A patent/EP2727910B1/en not_active Not-in-force
- 2008-09-15 PT PT88345046T patent/PT2209778E/pt unknown
- 2008-09-15 MY MYPI2010001186A patent/MY180558A/en unknown
- 2008-09-15 EP EP12181665A patent/EP2573087A1/en not_active Withdrawn
- 2008-09-15 WO PCT/US2008/076401 patent/WO2009042435A1/en not_active Ceased
- 2008-09-15 ES ES08834504T patent/ES2393824T3/es active Active
- 2008-09-15 EP EP08834504A patent/EP2209778B1/en not_active Not-in-force
- 2008-09-19 TW TW097136197A patent/TWI423799B/zh not_active IP Right Cessation
- 2008-09-19 AR ARP080104095A patent/AR068628A1/es not_active Application Discontinuation
2010
- 2010-03-02 IL IL204264A patent/IL204264A/en not_active IP Right Cessation
- 2010-03-04 TN TNP2010000100A patent/TN2010000100A1/fr unknown
- 2010-03-29 ZA ZA2010/02206A patent/ZA201002206B/en unknown
- 2010-04-14 MA MA32775A patent/MA31779B1/fr unknown
- 2010-04-21 CO CO10046631A patent/CO6270223A2/es not_active Application Discontinuation
- 2010-04-21 CR CR11383A patent/CR11383A/es unknown
2011
- 2011-03-29 ZA ZA2011/02350A patent/ZA201102350B/en unknown
2012
- 2012-06-11 US US13/493,616 patent/US8853409B2/en not_active Expired - Fee Related
2014
- 2014-09-23 US US14/494,430 patent/US9079890B2/en not_active Expired - Fee Related
2015
- 2015-03-12 CR CR20150131A patent/CR20150131A/es unknown

Also Published As

Publication number	Publication date
US9079890B2 (en)	2015-07-14
US8212045B2 (en)	2012-07-03
ZA201002206B (en)	2011-06-29
CN101868459B (zh)	2013-12-18
EP3078662A1 (en)	2016-10-12
US20100204240A1 (en)	2010-08-12
MA31779B1 (fr)	2010-10-01
CA2699718C (en)	2014-05-27
MY180558A (en)	2020-12-02
TN2010000100A1 (en)	2011-09-26
BRPI0816881A2 (pt)	2015-03-17
UA101166C2 (ru)	2013-03-11
ES2393824T3 (es)	2012-12-28
CR11383A (es)	2010-08-13
WO2009042435A8 (en)	2009-10-08
EP2573087A1 (en)	2013-03-27
AU2008305294A1 (en)	2009-04-02
KR20100080809A (ko)	2010-07-12
WO2009042435A1 (en)	2009-04-02
CR20150131A (es)	2015-04-30
PL2209778T3 (pl)	2013-02-28
CA2699718A1 (en)	2009-04-02
EP2727910B1 (en)	2016-03-16
JP5722037B2 (ja)	2015-05-20
HRP20120814T1 (hr)	2012-11-30
HK1197821A1 (en)	2015-02-18
SI2209778T1 (sl)	2012-12-31
CN101868459A (zh)	2010-10-20
US8853409B2 (en)	2014-10-07
TWI423799B (zh)	2014-01-21
NZ583538A (en)	2012-06-29
MX2010002772A (es)	2010-03-31
IL204264A (en)	2015-06-30
US20120277242A1 (en)	2012-11-01
TW200914007A (en)	2009-04-01
ES2569734T3 (es)	2016-05-12
EP2727910A1 (en)	2014-05-07
HK1145498A1 (en)	2011-04-21
EP2209778A1 (en)	2010-07-28
AU2008305294B2 (en)	2012-11-29
US20150057448A1 (en)	2015-02-26
ZA201102350B (en)	2012-09-26
PT2209778E (pt)	2012-12-06
AR068628A1 (es)	2009-11-25
EA201000515A1 (ru)	2010-10-29
EP2209778B1 (en)	2012-08-29
CO6270223A2 (es)	2011-04-20
JP2010540443A (ja)	2010-12-24
KR101566042B1 (ko)	2015-11-04
EA019104B1 (ru)	2014-01-30

Publication	Publication Date	Title
ZA201102350B (en)	2012-09-26	Pyridin-2-yl-amino-i,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
ZA200806510B (en)	2009-11-25	Heterobicyclic sulfonamide derivatives for the treatment of diabetes
DK2069374T4 (da)	2021-10-18	Krystallinske solvater af (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl)phenyl)-d-glucitolderivater med alkoholer som sglt2-inhibitorer til behandling af diabetes
NO20080622L (no)	2008-03-26	Disykloalkylurea-glukokinase aktivatorer
BRPI0914772A2 (pt)	2015-10-20	compostos heterocíclicos 1,2-dissubstituídos
EA200900877A1 (ru)	2010-02-26	Пиперидиновые агонисты gpcr
DK2114386T3 (da)	2013-03-18	Farmaceutisk sammensætning til behandling af diabeteskomplikationer
CL2008001049A1 (es)	2008-08-08	Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
BRPI0817096A2 (pt)	2017-05-02	análogos de tiazolidinodiona para o tratamento de hipertensão
CL2009000889A1 (es)	2010-07-19	Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus.
DK2300443T3 (da)	2013-02-18	Triazolderivater, der er anvendelige til behandling af sygdomme
IL199673A0 (en)	2010-04-15	5-(1,3,4- oxadiazol-2-yl)-1h-indazole and 5-(1,3,4 thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes
ZA200706294B (en)	2008-09-25	Roflumilast for the treatment of diabetes mellitus
CL2007001597A1 (es)	2008-05-16	Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes
CL2007001530A1 (es)	2008-01-04	Compuestos derivados de tiazol, inhibidores de fbpasa; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de diabetes mellitus tipo i, ii y iii, desequilibrio de glucosa en ayunas, desequilibrio en la tolerancia de la glucosa y complicaciones de la diabetes.
DK2228441T3 (da)	2013-09-08	Enzym, der er involveret i syntese af equol.
ZA201006827B (en)	2011-05-25	Carboxamide-heteroaryl derivatives for the treatment of diabetes
ZA201008657B (en)	2011-10-26	4,5-dihydro-oxazol-2-yl derivatives
PT2056805E (pt)	2011-09-02	Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
CL2008000110A1 (es)	2008-05-16	Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
IL177232A0 (en)	2006-12-10	Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
DK2266990T3 (da)	2013-01-07	3-PHENYLPYRAZOLO(5,1-b)THIAZOLFORBINDELSE
IL211267A0 (en)	2011-04-28	Oxadiazole derivatives for the treatment of diabetes
IL189928A0 (en)	2008-08-07	Thiophene derivatives for the treatment of diabetes
DK2268624T3 (da)	2013-11-04	Arylpyrazinon-derivater som insulin-sekretions-stimulatorer, fremgangsmåde til opnåelse deraf og anvendelse deraf til behandlingen af diabetes